RapidAI is a leading player in leveraging artificial intelligence to address critical neurovascular and vascular conditions, with a mission to revolutionize care for such life-threatening conditions. Established in 2011, the company has made significant strides in the medical field by empowering healthcare professionals with AI-driven solutions that optimize clinical decision-making and patient workflow.
With a strong focus on leveraging data intelligence gathered from over 10 million scans across 2,000 hospitals in 100 countries, RapidAI's platform offers unparalleled insights into patient care coordination. This has led to a transformative impact, providing care teams with an unprecedented level of patient visibility, ultimately leading to improved patient outcomes.
RapidAI's significant $75.00M Series C investment on 27 July 2023 from Vista Credit Partners underscores the confidence of investors in the company's innovative approach. The investment signifies not only a substantial influx of capital but also an affirmation of belief in RapidAI's potential to further redefine the intersection of AI and patient care.
Operating at the nexus of AI, Health Care, and Medical Devices, RapidAI's United States headquarters serves as the hub for its global efforts, positioning the company as a frontrunner in the ongoing evolution of medical technology and care delivery.
Overall, as a key player in an increasingly crucial segment of the healthcare industry, RapidAI's trajectory showcases promise and potential for addressing critical unmet needs, with the latest investment serving as a testament to its continued growth and impact.Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series C | $75.00M | 1 | Vista Credit Partners | 27 Jul 2023 |
Series B | $25.00M | 1 | Lennertz & Co. | 17 Sep 2020 |
No recent news or press coverage available for RapidAI.